

**Tristel plc**

**("Tristel" or the "Company")**

**Issue of Equity**

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that, following an exercise of options, it has issued and allotted 17,000 new ordinary shares in the Company (“Ordinary Shares”). Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around the 14 June 2021.

The new Ordinary Shares will rank *pari passu* with the existing shares of the Company. Following the exercise of options, the Company's issued share capital consists of 47,094,443 Ordinary Shares. Accordingly, the figure of 47,094,443 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

**For further information please contact:**

|  |  |
| --- | --- |
| Tristel plc | Tel: 01638 721 500 |
| Paul Swinney, Chief Executive Officer |  |
| Liz Dixon, Finance Director |  |
|  |  |
| **Walbrook PR Ltd** | Tel: 020 7933 8780 or tristel@walbrookpr.com |
| Paul McManus | Mob: 07980 541 893 |
| Lianne Cawthorne | Mob: 07854 391 303  |
|  |  |
| **finnCap** | Tel: 020 7220 0500 |
| Geoff Nash / Charlie Beeson, Corporate Finance |  |
| Alice Lane, ECM |  |